In vivo assay of human NK-dependent ADCC using NOD/SCID/γcnull (NOG) mice

Biochemical and Biophysical Research Communications

Volumn 399, Issue 4, 2010, Pages 733-737

  Shiokawa, Miho ^a,b   Takahashi, Takeshi ^a   Murakami, Akihiro ^b   Kita, Shoichi ^b   Ito, Mamoru ^c   Sugamura, Kazuo ^a,d   Ishii, Naoto ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Medical & Biological Laboratories Co Ltd   (Japan)

^c CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^d MIYAGI CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Antibody; Antibody dependent cellular cytotoxicity (ADCC); NK cell; NOG mice

Indexed keywords

RITUXIMAB; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; DAUDI CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCID MOUSE; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; DRUG SCREENING; IMMUNOLOGY; NONOBESE DIABETIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; HUMANS; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 77956261949     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.07.145     Document Type: Article

References (16)

1. Liu X.Y., Pop L.M., Vitetta E.S. Engineering therapeutic monoclonal antibodies. Immunol. Rev. 2008, 222:9-27.
2. Garrard L.J., Yang M., O'Connell M.P., Kelley R.F., Henner D.J. Fab assembly and enrichment in a monovalent phage display system. Biotechnology 1991, 9:1373-1377.
3. Jakobovits A., Amado R.G., Yang X., Roskos L., Schwab G. From XenoMouse technology to panitumumab: the first fully human antibody product from transgenic mice. Nat. Biotechnol. 2007, 25:1134-1143.
4. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., Shitara K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278:3466-3473.
5. Barkas T., Al-Khateeb S.F. Serum factors influencing antibody-directed cell-mediated cytotoxicity (ADCC) and their effects on the detection of immune complexes by inhibition of ADCC. Immunology 1979, 36:299-306.
6. Timonen T. Natural killer cells: endothelial interactions, migration, and target cell recognition. J. Leukoc. Biol. 1997, 62:693-701.
7. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 2007, 7:118-130.
8. Herlyn D.M., Steplewski Z., Herlyn M.F., Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 1980, 40:717-721.
9. Ishida T., Ishii T., Inagaki A., Yano H., Kusumoto S., Ri M., Komatsu H., Iida S., Inagaki H., Ueda R. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia 2006, 20:2162-2168.
10. Ito A., Ishida T., Yano H., Inagaki A., Suzuki S., Sato F., Takino H., Mori F., Ri M., Kusumoto S., Komatsu H., Iida S., Inagaki H., Ueda R. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol. Immunother. 2009, 58:1195-1206.
11. Ito A., Ishida T., Utsunomiya A., Sato F., Mori F., Yano H., Inagaki A., Suzuki S., Takino H., Ri M., Kusumoto S., Komatsu H., Iida S., Inagaki H., Ueda R. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2Rgamma(null) mice in vivo. J. Immunol. 2009, 183:4782-4791.
12. Inamoto T., Yamada T., Ohnuma K., Kina S., Takahashi N., Yamochi T., Inamoto S., Katsuoka Y., Hosono O., Tanaka H., Dang N.H., Morimoto C. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin. Cancer Res. 2007, 13:4191-4200.
13. Kretz-Rommel A., Qin F., Dakappagari N., Ravey E.P., McWhirter J., Oltean D., Frederickson S., Maruyama T., Wild M.A., Nolan M.J., Wu D., Springhorn J., Bowdish K.S. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J. Immunol. 2007, 178:5595-5605.
14. Hernandez-Ilizaliturri F.J., Jupudy V., Ostberg J., Oflazoglu E., Huberman A., Repasky E., Czuczman M.S. Neutrophils contribute to the biological antitumor activity of Rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin. Cancer Res. 2003, 9:5866-5873.
15. Fujii E., Suzuki M., Matsubara K., Watanabe M., Chen Y.J., Adachi K., Ohnishi Y., Tanigawa M., Tsuchiya M., Tamaoki N. Establishment and characterization of in vivo human tumor models in the NOD/SCID/gamma(c)(null) mouse. Pathol. Int. 2008, 58:559-567.
16. Dewan M.Z., Terashima K., Taruishi M., Hasegawa H., Ito M., Tanaka Y., Mori N., Sata T., Koyanagi Y., Maeda M., Kubuki Y., Okayama A., Fujii M., Yamamoto N. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB. J. Virol. 2003, 77:5286-5294.